Related coverage linked through entity extraction aliases.
May 13, 2026
A phase 2 trial in high-risk smoldering multiple myeloma found all 20 patients treated with cilta-cel became MRD-negative within two months and remained so after 15.3 months. No disease progression, death, dose-limiting toxicities, or high-grade side effects were observed.
Apr 15, 2026
Johnson & Johnson raised its full-year forecast after stronger-than-expected quarterly results driven by cancer, immunology and neuroscience drugs. Sales were $24.56 billion and adjusted earnings were $2.46 per share, with Innovative Medicines sales rising 10.0% to $15.76 billion.
Apr 11, 2026
Johnson & Johnson shares hit a 52-week high after the company reported 2025 revenue of $94.19 billion and forecast 2026 revenue above $100 billion. The company also filed a shelf registration and said Innovative Medicine growth offset pressure from Stelara.
Mar 29, 2026
Johnson & Johnson reported strong Q4 2025 earnings with $2.46 adjusted EPS and $24.56 billion in sales, beating estimates. The company faces over 67,000 active talc lawsuits following recent trial losses while projecting 2026 sales of $100-101 billion and maintaining a robust pipeline with recent FDA approvals and breakthrough designations.
Mar 17, 2026
CAR T-cell therapy demonstrates near-98% response rates in multiple myeloma trials, but only 2.6% of eligible patients receive treatment. Black patients face substantially lower access, with structural and institutional barriers limiting availability of the specialized therapy.
Mar 17, 2026
Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.
Mar 15, 2026
CAR T-cell therapy is delivering unprecedented results for multiple myeloma patients, with CARTITUDE-1 trial data showing one-third of patients remaining progression-free for five years or more, raising the possibility of cure for some patients.
Feb 27, 2026
Novel CELMoD agents are being evaluated to address T-cell exhaustion in multiple myeloma patients, while CAR T-cell therapy CARVYKTI shows longer-term survival benefits. Nearly 200,000 people in the U.S. live with this blood cancer.
Feb 20, 2026
Johnson & Johnson announced a more than $1 billion investment to build a new cell therapy manufacturing facility in Lower Gwynedd, Pennsylvania, creating 500 skilled biomanufacturing jobs and 4,000 construction jobs as part of its $55 billion U.S. investment strategy through early 2029.
Feb 26, 2026
CAR T-cell therapy is delivering high remission rates for multiple myeloma patients, with improved handoff communication reducing infection risks. FDA-approved BCMA-targeting products show response rates from 72% to 98% in heavily pretreated patients.
Feb 18, 2026
Preclinical and early clinical data show carfilzomib can restore BCMA expression on myeloma cells after CAR T-cell therapy failure, with 6 of 10 patients experiencing renewed clinical responses in a small study.
Feb 18, 2026
Johnson & Johnson announced plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, creating over 500 biomanufacturing jobs and 4,000 construction positions as part of its $55 billion U.S. investment commitment.
